Seed

Bluegrass Pharmaceuticals is a discovery-stage biotech company dedicated to advancing the next generation of Lipid Nanoparticles for superior vaccination efficacy.

While vaccines remain a cornerstone of modern medicine, innovation in protein-based vaccines—which represent over 50% of all vaccines administered—has lagged behind the recent mRNA surge. Current protein-based vaccines rely on aluminum salts (a technology dating back to the 1930s) to boost immune response, yet many still require multiple doses for lasting protection.

In hospitals and private practices, patient photos are essential for documentation, diagnosis, and outcomes tracking — yet most providers still use unsecured smartphone cameras and inconsistent processes.

This leads to HIPAA violations, lost or misfileed images, and inconsistent before-and-after documentation that diminishes clinical and marketing value.

ThorafiX addresses Proximal Junctional Kyphosis (PJK), a debilitating complication affecting up to 46% of adult spinal deformity cases. PJK causes structural breakdown at the top of long spinal fusions, leading to vertebral collapse, severe pain, and costly revision surgeries.

Current approaches—pedicle screw-only constructs or soft-tissue preservation—fail to provide lasting biomechanical protection.

Every year, preventable deaths occur due to gaps in human monitoring—officers can’t watch every cell, and caregivers can’t reach every room. Traditional solutions rely on wearables, invasive cameras, or manual checks that compromise privacy or fail when devices are forgotten or refused.

Rahm Sensor Development addresses this critical need with contact-free radar, thermal, and intelligent video fusion processed entirely on-device.

DermiSense is a medical technology company revolutionizing diagnostic testing by offering a painless alternative to invasive blood draws.

Traditional blood sampling is expensive, resource-intensive, requires specialized training, and often causes patient anxiety—limiting frequent and decentralized testing.

SYMBIO-X Health is a Vanderbilt spin-out developing the first hardware-firmware co-designed wearable that delivers Doppler-grade cardiac valve metrics continuously at home—eliminating dependence on facility-based echo/MRI.

Kifa Therapeutics is a precision-neurology company developing first-in-class, mutant-selective kinase inhibitors to halt Parkinson’s disease at its genetic source.

Our lead program targets the G2019S mutation in LRRK2—the most common genetic cause of Parkinson’s—which drives neuronal toxicity through hyperactivation of the LRRK2 kinase pathway.

InTailor Bariatrics is advancing endoscopic automatic gastroplasty—an innovative technology that automates tissue acquisition, configuration, and fixation for consistent, reproducible outcomes and widespread physician adoption.

Avast Therapeutics, Inc. is a preclinical-stage biopharmaceutical company developing first-in-class, non-invasive peptide therapeutics to treat neurodegenerative diseases, including Parkinson’s and Alzheimer’s.

Founded by University of Kentucky neuroscientists, Avast holds an exclusive license to a proprietary collection of small peptides capable of:

SARC Solutions addresses a critical gap in cybersecurity: traditional endpoint detection and response (EDR) tools fail to protect high-value infrastructure in energy systems and data centers.

As environments shift to virtualization, edge computing, and always-on control systems, conventional platforms become ineffective—they are OS-dependent, resource-intensive, and vulnerable to tampering on SCADA systems, embedded devices, and virtual machines.